News
Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could ...
Al Jazeera on MSN1d
Wegovy maker Novo Nordisk warns of layoffs as competition grows
Novo Nordisk’s outgoing CEO, Lars Fruergaard Jorgensen, has warned that layoffs at the Danish pharmaceutical giant could be ...
Novo Nordisk continues to deliver double-digit revenue and profit growth, driven by both its diabetes and obesity drug ...
Novo Nordisk cautioned on Wednesday that it expects continued competition this year from copycat versions of its Wegovy ...
Novo Nordisk said second-quarter sales of its blockbuster Wegovy weight-loss drug soared 67% on year, despite waves of U.S.
Orforglipron led to 12.4% weight loss after 72 weeks while Novo Nordisk’s oral therapy showed a 13.6% drop in weight.
Otte took on the title in February, the culmination of nearly 25 years spent with the Danish drugmaker. As of his departure ...
Novo Nordisk CFO Karsten Munk Knudsen tells Yahoo Finance the company understands the pressure it is under to deliver better ...
Novo Nordisk is to cut costs as the Wegovy-maker battles competition from rival Eli Lilly and copycat versions of its obesity ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback